DOCSLIB.ORG

Upfront IL-18 Stakes Claim As an AMD Therapy in Practice Strategies For

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Upfront IL-18 Stakes Claim As an AMD Therapy in Practice Strategies For APRIL 2014 # 07 Upfront In Practice NextGen Profession IL-18 stakes claim as an Strategies for What are the benchmarks for Making conferences a AMD therapy managing glaucoma research in DME? family affair 14 36 –37 42 – 44 48 – 49 Strong Any nucleus from soft to hardest, any incision from 1.6 to 3.2 mm, fast, safe and the AC always stable. That’s easyPhaco®. CortexModeTM for precisely con- trolled cortical clean-up. HF capsulotomy for difficult cases. 1200 cuts anterior vitrectomy. Beautiful So easy to operate! DirectAccess® to any function without confusion. Programmable for 20 surgeons. Bright, easy to read display. A marvel of design, brings a friendly note in your OR. Unique Truly portable, 5 kg, fits in a pilot’s case. HFDS ab interno glaucoma function, the future of combined glaucoma surgery. Fantastic toe tip of flow control. Built-in compressor. Just plug to 90-230 V. For You Lets you enjoy most advanced surgery from low to highest volume in any set-up at controlled costs. www.oertli-catarhex3.com Breathtaking Ecknauer+Schioch ASW Who’s Who on the Cover? 1. Carmen Puliafito 21. Claude Burgoyne 41. Kazuo Tsubota 61. Harry Quigley 81. Jim Mazzo 2. Bill Aylward 22. Robert Weinreb 42. Robert Ritch 62. Oliver Findl 82. Paul Kaufman Strong 3. George Spaeth 23. Robert Osher 43. Napoleone Ferrara 63. Usha Chakravarthy 83. Abhay Vasavada 4. Martine Jager 24. David Garway-Heath 44. Emily Chew 64. Roger Hitchings 84. Neil Bressler Any nucleus from soft to hardest, any incision from 5. Eberhardt Zrenner 25. Robert E Grant 45. Daniel Palanker 65. James Fujimoto 85. Renato Ambrosio 1.6 to 3.2 mm, fast, safe and the AC always stable. 6. Alan Scott 26. David Abramson 46. Alfred Sommer 66. Phillip Rosenfeld 86. Dennis Lam That’s easyPhaco®. CortexModeTM for precisely con- 7. Giovanni Staurenghi 27. Hannah Faal 47. Gerhard Zinser 67. Tetsuya Yamamoto 87. David Chang 8. Daniel Martin 28. Farhad Hafezi 48. Sunil Shah 68. Jean Bennett 88. Gerd Auffarth trolled cortical clean-up. HF capsulotomy for difficult 9. Tin Aung 29. Tony Adamis 49. David Parke 69. Greg Hageman 89. Richard Lindstrom cases. 1200 cuts anterior vitrectomy. 10. Charles McGhee 30. Peter Barry 50. Xiulan Zhang 70. Mark Tso 90. Theo Seiler 11. Seang Mei Saw 31. Ningli Wang 51. Richard Abbott 71. Nag Rao 91. Amar Agarwal Beautiful 12. Michael Mrochen 32. Eduardo Alfonso 52. Ursula Schmidt-Erfurth 72. Rudy Njuits 92. Donald Tan ® 13. David Pyott 33. Paul Sieving 53. Mark S Humayun 73. Robert Nussenblatt 93. David Huang So easy to operate! DirectAccess to any function 14. Allen Foster 34. Paul Foster 54. Stefan Seregard 74. Ioannis Pallikaris 94. Frank Holz without confusion. Programmable for 20 surgeons. 15. Susanne Binder 35. Kuldev Singh 55. George Waring 75. Ike Ahmed 95. Jorge Alio Bright, easy to read display. A marvel of design, 16. Boris Stanzel 36. Robert Stamper 56. Shigeru Kinoshita 76. John Kanellopoulos 96. Claes Dohlman 17. Stanley Chang 37. Emilio Campo 57. Joan Miller 77. Lawrence Yannuzzi 97. Dan Albert brings a friendly note in your OR. 18. Roberto Bellucchi 38. R. Rand Allingham 58. Evan Gragoudas 78. Marie-José Tassignon 98. Bruce Spivey 19. Paul Mitchell 39. Peng Khaw 59. Hugh Taylor 79. Al Maguire 99. John Marshall Unique 20. Cynthia Roberts 40. Bradley Straatsma 60. Carol Shields 80. Paul Sternberg 100. Harminder Dua Truly portable, 5 kg, fits in a pilot’s case. HFDS ab interno glaucoma function, the future of combined 12 14 18 7 9 10 11 19 21 glaucoma surgery. Fantastic toe tip of flow control. 13 15 16 4 5 6 Built-in compressor. Just plug to 90-230 V. 3 8 35 17 20 23 24 34 22 25 2 31 33 36 40 26 32 38 27 For You 53 41 30 37 39 1 29 Lets you enjoy most advanced surgery from low to 28 52 42 43 44 54 highest volume in any set-up at controlled costs. 49 50 51 55 56 45 58 67 59 www.oertli-catarhex3.com 68 46 47 48 69 57 66 63 64 65 81 82 71 79 80 83 70 85 60 61 62 84 86 77 78 90 89 91 92 93 94 76 88 73 95 98 74 87 97 72 75 96 Breathtaking 99 100 Ecknauer+Schioch ASW Contents 36 17 48 03 Online This Month Upfront 10 iPhone eye imaging 07 Editorial The Power of the List 12 The Vitreomacular Interface By Richard Gallagher Influences AMD Outcomes 13 Stats on stats 08 Contributors 14 Interleukin for a better wet AMD therapy On The Cover Feature 15 POAG Predisposition APRIL 2014 # 07 Power List pastiche of Sir Peter 17 The owerP List 2014 Upfront In Practice NextGen Profession IL-18 stakes claim as an Strategies for What are the benchmarks for Making conferences a AMD therapy managing glaucoma research in DME? family affair 14 36 –37 42 – 44 48 – 49 Blake’s “Sgt. Pepper’s Lonely So let us introduce to you Hearts Club Band” album cover The neo and only Theo Seiler (1967). And The Ophthalmologist’s Top 100 Band. 0414 TOP.indd 1 04/04/2014 15:49 ISSUE 07 - APRIL 2014 Editor - Mark Hillen [email protected] Editorial Director - Richard Gallagher [email protected] Graphic Designer - Marc Bird [email protected] Managing Director - Andy Davies [email protected] Director of Operations - Tracey Peers [email protected] Publishing Director - Neil Hanley [email protected] Audience Development Manager - Tracey Nicholls [email protected] Digital Content Manager - David Roberts 14 [email protected] Editor, Custom Publishing - Iestyn Armstrong-Smith [email protected] In Practice 50 Traffic and Administration Manger - Claire Lally 34 Selecting for Patient Success [email protected] The best diagnostic tools ensure the right procedures are selected for patients, improving outcomes Published by for refractive surgery. Texere Publishing Limited, Booths Hall, Booths Park, 36 Glaucoma Management Strategies Chelford Road, Knutsford, Cheshire, When eyedrops aren't the WA16 8GS, UK answer, surgical techniques General enquiries: and drainage devices are what Profession www.texerepublishing.com helps glaucoma patients. [email protected] 48 Quality Family Time at a Congress +44 (0) 1565 752883 Taking the whole family to [email protected] conference locations gives you a NextGen new perspective on the places you visit. Distribution: The Ophthalmologist distributes 42 Benchmarking DME 17,934 printed copies and 7,295 electronic copies to a targeted Analyzing the last five years of European list of industry the literature on diabetic macular Sitting Down With professionals. edema tells a story of what the ISSN 2051-4093 priorities are and who is making 50 Dan Myers, President and CEO the most contribution. of Alimera Sciences, Inc. Corneal response due to an air ® OCULUS Corvis ST pulse, 140 images in 31 ms. 13.282 ms 15.114 ms 17.175 ms 19.007 ms 21.068 ms 22.900 ms Highspeed Scheimpflug camera visualizes the 24.961 ms future of diagnosis 28.854 ms 30.915 ms Please note: The availability of the products and features may differ in your country. Specifications and design are subject to change. Please contact your local distributor for details. Highspeed Scheimpflug camera in combination with non-contact tonometer: • Precise measurement of the IOP • Precise measurement of corneal thickness • Information on biomechanical response • Screening for ectasia www.oculus.de The Ophthalmologist Corvis ST Produkt 210x266 e 03.14.indd 1 31.03.2014 13:00:40 Corneal response due to an air ® OCULUS Corvis ST pulse, 140 images in 31 ms. The Power of the List Editorial The Ophthalmologist Power List 2014 is this publication’s catalog of the 100 most influential people in ophthalmology today. 13.282 ms hy generate a Top 100? Of the many reasons, 15.114 ms the chief one is to catalog and celebrate progress. I believe that most ophthalmologists would agree that these are among the best 17.175 ms of times for the profession; an age of wisdom rather than of Wfoolishness. Your accomplishments include: the development of new surgical techniques, drugs and ophthalmic devices; breakthroughs in the understanding of biology, pathology and epidemiology; 19.007 ms improvements (arguably) in health care administration and delivery, and the growth of an industry and infrastructure to meet the complex medical needs of patients. 21.068 ms This progress is driven by people, and those driving this progress deserve recognition. One great way of doing this is to highlight the achievements of ophthalmology’s most influential contributors. And that’s what the Power List is: a celebration, acknowledgement and offer 22.900 ms of gratitude to some of the major contributors to ophthalmology today. I don’t claim that this is definitively the top 100 people in Highspeed Scheimpflug ophthalmology. It’s a subjective list, initially compiled from our 24.961 ms readers’ contributions. If it has shocking omissions or inclusions – do camera visualizes the let us know and help us by submitting nominations next year. The list was developed in three stages. In stage 1, we invited readers to nominate people that they thought deserved recognition future of diagnosis 28.854 ms – only those nominated were considered. In stage 2, a jury of five noted ophthalmologists (who prefer to remain anonymous and were modest enough not to vote for themselves) selected their top 100 30.915 ms Please note: The availability of the products and features may differ in your country. Specifications and design are subject to change. Please contact your local distributor for details.
Load more

Recommended publications
  • This Is a Program Where Learning Is Valued and the Educational Experience Is Tangible
    “This is a program where learning is valued and the educational experience is tangible. You will learn a vocation, but it differs from many other schools in that HMS is a very academic environment. This is a place where a trainee can approach a faculty member and count on getting help. People coming from other institutions are simply struck by the emphasis we place on medical education.” — Simmons Lessell, MD, Director of Ophthalmic Medical Student Education, Harvard Medical School 113 M Today, about 1 in 6 ophthalmology department EDICAL Innovate. Train. Mentor. Inspire. chairs in academic institutions across the U.S. and EDUCATION Medical education is integral to the HMS Department of Ophthalmology’s mission, Canada conducted postdoctoral training at HMS. and trainees receive the finest ophthalmic education in the world. The depart- ment supports full-time faculty in every ophthalmic subspecialty, giving residents S a comprehensive grounding in ocular disease and management. Moreover, fellows ETTING have the opportunity to gain further clinical expertise or pursue in-depth research students have the opportunity to • Visual functions and developing mology is an area of medicine they evaluate, triage, and manage pa- technologies for visual rehabilita- would like to pursue. Elective rota- S in one or more of nine subspecialty areas. Under the exceptional leadership of John tients, and learn how to use special- tion tions also provide excellent train- TANDARD I. Loewenstein, MD, HMS Ophthalmology Vice Chair for Medical Education and ized ophthalmic equipment, includ- ing for students who may choose a ing the slit-lamp biomicroscope, the According to Dr.
    [Show full text]
  • Interferon May Offer First Drug Therapy for Diabetic Retinopathy
    CLINICAL NEWS he says, "studies of angiogenesis have led to a new understanding of some of the vascular complications of diabetes." Angiogenesis was first linked to Interferon May Offer First Drug interferon —10 yr ago. Until then, in- Therapy for Diabetic terferon has been known mainly for its ability to stimulate the production of T Retinopathy lymphocytes. Then studies showed that the protein could slow the migration of New Research Showing That a-Interferon endothelial cells during the growth of new blood vessels. Soon after, other re- Blocks New Blood Vessel Formation in the Iris searchers showed that a-interferon slows down blood vessel growth in of Monkeys May Point the Way to New mice. In 1989, Carl W. White and Treatment for Diabetes Retinopathy. colleagues at the University of Colorado Health Sciences Center in Denver used a-interferon to treat a child with a he- mangioma, a mass resulting from the proliferation of capillaries. Hemangio- ye researchers are looking to the sudden loss of vision. The scarring that mas can occur anywhere in the body, immune system for new ways to accompanies recurrent hemorrhaging and can be fatal when they occur in E prevent, treat, or reverse prolifera- can lead to permanent loss of vision. certain organs. White's patient had a tive retinopathy, the most serious form Approximately 700,000 people hemangioma in the lung, a rare and of diabetic retinopathy. in the United States have proliferative usually fatal condition. Treatment with Proliferative retinopathy is retinopathy, with —65,000 new cases interferon, however, caused the heman- marked by the development of new being diagnosed each year.
    [Show full text]
  • Mass. Eye and Ear and Schepens Eye Research Institute Unite Forces
    Eyewitness THE NEWSLEttER OF THE HARVARD MEDICAL SCHOOL Department of Ophthalmology NOTES FROM THE CHAIR FALL/WINTER 2011 #18 Mass. Eye and Ear and Schepens Eye Research Institute Unite Forces ushing new boundaries that propel vision research forward is a hallmark of our department Pand, in June, led us to fulfill an exciting and historical agreement with the announcement that the Boards of two of our esteemed affiliates - Massachusetts Eye and Ear Infirmary and Schepens Eye Research Institute (Schepens) – have agreed to join forces. This powerful new alliance creates the largest and most dynamic basic and clinical ophthalmology research enterprise in the world, uniting a passionately dedicated team of nearly 100 full-time HMS investigators and clinician scientists whose talents and expertise span a full spectrum of eye diseases and scientific disciplines. Both institutions will operate under the direction of Mass. Eye and Ear’s Board of Directors, while Schepens will retain its name and continue as a non-profit research center. Joan W. Miller, MD Chief and Chair continues on page 4 Schepens in the Mass. Eye and Ear Family ass. Eye and Ear has long enjoyed a close Mcollaboration with nearby Schepens Eye Research Institute (Schepens), a leading eye research organization. In June 2011, Schepens and Mass. Eye and Ear officially combined forces to create the world’s largest and most robust basic and clinical ophthalmology research enterprise. Nearly 100 full-time investigators and clinician scientists form a full spectrum of ophthalmic talent and resources dedicated to accelerating bench-to-bedside discoveries. Schepens triumvirate leadership team (l to r): Reza Dana, MD, MPH, MSc, History of Schepens Eye Research Institute Patricia D’Amore, MD, MBA, Eliezer (Eli) Peli, MSc, OD In the late 1940s, as a researcher in the Howe Laboratory was later renamed the Schepens Eye Research Institute of Ophthalmology at Mass.
    [Show full text]
  • New VEGF Antagonists in AMD – New Quandaries Abound
    4 By Nick Lane PhD New VEGF antagonists in AMD – new quandaries abound predominantly classic CNV most suitable But here is the rub. Ranibizumab is a Of course, in both advanced cancer and for treatment with verteporfin PDT. molecular cousin of a larger antibody, wet AMD, angiogenesis is an important Even so, despite the relatively slow known as bevacizumab (molecular weight factor in determining outcome. Genentech disease progression, patients treated with 148 kDa), marketed by Genentech as felt that bevacizumab was too big to ® ffective vascular-endothelial growth- ranibizumab experienced a mean increase Avastin . Engineered on the DNA level, penetrate the retina by intravitreal factor (VEGF) antagonists have been of seven letters VA at 12 months, while ranibizumab has several specific base injection; and while life-threatening adverse a long time coming, after first being patients in the control group had a mean changes that increase its affinity to VEGF. events (a higher risk of thromboembolic E decrease of 10.5 letters. Some 34% of the The FDA approved bevacizumab for events such as stroke and MI) might be proposed back in the 1970s; but now, like London buses, three have arrived at once 0.5 mg-treatment group experienced a treating advanced colorectal cancer in acceptable in treating advanced cancer, for the treatment of wet AMD. Far from better than15-letter gain in VA, compared February 2004, and it is still in trials for systemic treatment with bevacizumab for being just ‘me-too’ drugs in the same class, with 4.6% in the control group. other forms of cancer.
    [Show full text]
  • 779Th Meeting of the New England Ophthalmological Society
    779th meeting of the New England Ophthalmological Society NEW DRUGS IN OPHTHALMOLOGY: FROM DROPS TO DRIPS with The Stephen Foster Lecture on Ocular Inflammation RETINAL DETACHMENT: DIAGNOSIS, MANAGEMENT, AND CHALLENGES with The Joan W. Miller, MD Lecture April 24, 2020 Virtual meeting available at WWW.NEOS-EYES.ORG th th The 779 Meeting of the 779 meeting of The New England Ophthalmological Society, Inc. A Public Foundation for Education in Ophthalmology Virtual meeting available at WWW.NEOS-EYES.ORG The New England Ophthalmological Society, Inc. A Public Foundation for Education in Ophthalmology April 24, 2020 NEW DRUGS IN OPHTHALMOLOGY: FROM DROPS TO DRIPS VIRTUAL MEETING AVAILABLE AT April 24, 2020 WWW.NEOS-EYES.ORG Lucia Sobrin, MD, MPH, Moderator and Program Committee Coordinator ------------------------------------------------------- NEW DRUGS IN OPHTHALMOLOGY: FROM DROPS TO DRIPS WITH THE STEPHEN FOSTER LECTURE ON OCULAR INFLAMMATION RETINAL DETACHMENT: DIAGNOSIS, MANAGEMENT, AND CHALLENGES Peter Chang, MD, Moderator Lucia Sobrin, MD, MPH, Moderator and Program Committee Coordinator Brian Kim, MD, Program Committee Coordinator RETINAL DETACHMENT: DIAGNOSIS, MANAGEMENT, AND CHALLENGES ------------------------------------------------------- WITH JOAN W. MILLER, MD LECTURE Peter Chang, MD, Moderator Brian Kim, MD, Program Committee Coordinator AMA Credit Designation Statement The New England Ophthalmological Society designates this enduring material for a maximum of 4.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit AMA Credit Designation Statement commensurate with the extent of their participation in the activity. The New England Ophthalmological Society designates this enduring material for a maximum of 4.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit Accreditation Statement commensurate with the extent of their participation in the activity.
    [Show full text]
  • Angiogenesis
    Angiogenesis An Integrative Approach From Science to Medicine Angiogenesis An Integrative Approach From Science to Medicine Edited by William D. Figg Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA Judah Folkman Department of Surgery, Harvard Medical School and Vascular Biology Program, Children’s Hospital Boston, Boston, Massachusetts, USA Editors William D. Figg Judah Folkman Medical Oncology Branch Department of Surgery Center for Cancer Research Harvard Medical School and National Cancer Institute Vascular Biology Program Bethesda, Maryland Children’s Hospital Boston USA Boston, Massachusetts USA ISBN: 978-0-387-71517-9 e-ISBN: 978-0-387-71518-6 DOI: 10.1007/978-0-387-71518-6 Library of Congress Control Number: 2007934647 © 2008 Springer Science+Business Media, LLC All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science + Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made.
    [Show full text]
  • Judah Folkman 1933–2008
    Judah Folkman 1933–2008 A Biographical Memoir by Patricia K. Donahoe ©2014 National Academy of Sciences. Any opinions expressed in this memoir are those of the author and do not necessarily reflect the views of the National Academy of Sciences. MOSES JUDAH FOLKMAN February 24, 1933–January 14, 2008 Elected to the NAS, 1990 Moses Judah Folkman was born in 1933 in Cleveland, Ohio. He was the oldest child of a distinguished line of rabbis whose influence on the young man—particularly that of his father, Rabbi Jerome Folkman—is legendary. His mother, Bessie Schomer Folkman, instilled in him a love of science with bedtime stories about Newton, Pasteur, and Madame Curie. A move to Columbus during high school put Folkman under the tutelage of Robert Zollinger, who spotted him working at Ohio State University Hospital as a volunteer aide and invited him to work in his laboratory afternoons and weekends. There in the Zollinger Laboratory, where he worked throughout college, Folkman had the oppor- By Patricia K. Donahoe tunity to learn surgical skills and published a paper about liver cooling in the journal Surgery. He was accepted at Harvard Medical School in 1953 and worked in the laboratories of Robert E. Gross, from whom he learned the “obsessive perseverance” required for his future life as a surgeon scientist. Folkman also helped to develop a heart-lung bubble oxygenator, which was initially used for repair of ventricular septal defects, and he designed a prototype transistorized pacemaker with Massachusetts Institute of Technology graduate student Fred Vanderschmidt. The heart lung machine and the pacemaker, though perfected in other laboratories, provided the tools to realize Gross’s dream of innovating and making cardiac surgery routine for infants and children (Cooke 2001).
    [Show full text]
  • The Vision of One Special Patient
    THE NEWSLETTER OF THE HARVARD MEDICAL SCHOOL D epartment of Ophthalmology EyewitnessSPECIAL GRADUATION IssUE SPRING/SUMMER 2011 #17 NOTES FROM THE CHAIR procedures. As a graphic artist his visual The Vision of perception was particularly precious to him, and he certainly mourned its One Special Patient loss. However, he set out to find ways s an ophthalmologist specializing to adapt. A in blinding retinal diseases such as Rob moved into a senior independent age-related macular degeneration (AMD), living facility so that he wouldn’t spend I have always believed in life-long learning all of his energy managing day-to-day through journal articles, professional living. He discovered that many others societies, and the probing questions of our in the facility had vision problems and brilliant trainees. But it is from my patients developed a program of lectures and that I learn what no seminar or publication Dr. Joan Miller with Seymour Robins an exhibition by vendors of visual aids can teach: how they cope day-to-day with in 2008. Photo by Don Victor and equipment. He started to write the trappings of their disease, what they about living with macular degeneration, lose (and sometimes gain) along the way, how medical sharing his witty anecdotes in his prose. With his treatment affects their vision and their lives, and how they observational skills heightened by his training as a graphic often transcend the challenges of visual disability. artist, Rob fastidiously documented his altered visual Seymour “Rob” Robins was a remarkable individual and perceptions. In 2005, he published Vision Junkie: Essays a patient of mine from 1999 until his recent death at and Other Writings from the Parallel World of the Legally age 97.
    [Show full text]
  • Image of the Month the Human Choroid, Reconstructed in 3D
    APRIL 2016 # 29 Image of the Month Upfront Profession Sitting Down With The human choroid, Growing your own Benchmarking your practice Amar Agarwal, Chairman of reconstructed in 3D crystalline lens against your peers Dr Agarwal’s Eye Hospital 03 08 – 10 60 – 64 66 – 67 www.theophthalmologist.com DUAL-SEGMENT PUMP TECHNOLOGY + Precise fluidics + Pulsatile-free + Quick vacuum rise + Versatile performance PERFORMANCE IN EVERY DETAIL Superior chamber stability through superior engineering.†,1,2 That’s the Centurion® Effect. Active Fluidics™ Technology • Helps to Maintain Chamber Stability: Detects and compensates to help provide superior chamber stability3 compared to INFINITI®4 • Less Surge: Less surge at any tested vacuum level3,5 • More Consistent IOP4 : Up to 80% less surge area3,5 Contact your Alcon representative to schedule a demonstration and experience the Centurion® Effect for yourself. †As compared to the INFINITI® Vision System, bottle gravity system. 1. Lorente R, Fanney D, Injev V, Sharif-Kashani P. Quantification of occlusion break surge in peristaltic-based phacoemulsification systems. ASCRS-ASOA Symposium and Congress; April 25-29, 2014; Boston, USA.2. Nicoli M, Miller K, Dimalanta R, Loke D; Jules Stein Eye Institute, UCLA. IOP Stability Measurement and Comparison Between Gravity-Fed and Actively Controlled Phacoemulsification Systems. 2014. 3. Sharif-Kashani P, Fanney D, Injev V. Comparison of occlusion break responses and vacuum rise times of phacoemulsification systems. BMC Ophthalmol. 2014;14:96. 4. Nicoli CM, Dimalanta R, Miller K. Experimental anterior chamber maintenance in active versus passive phacoemulsification fluidics systems. J Cataract Refract Surg. 2016;42(1):157-162. 5. Alcon data on file.
    [Show full text]
  • Massachusetts Eye and Ear Infirmary Quality and Outcomes 2012
    MASSACHUSETTS EYE AND EAR INFIRMARY Quality and Outcomes 2012 Clinical Leadership in Quality: 2011-2012 Sunil Eappen, M.D. Members of the Mass. Eye Assistant Professor, Harvard Medical School, Harvard School and Ear Quality Steering of Public Health Committee include: Chief Medical Officer, Chief of Anesthesiology, Massachusetts Eye and Ear Infirmary Linda Belkner, R.N. Director, Quality and Joan W. Miller, M.D. Patient Safety Henry Willard Williams Professor of Ophthalmology, Harvard Medical School Chief and Chair, Department of Ophthalmology, Mary Kennedy Massachusetts Eye and Ear Infirmary Risk Manager Massachusetts General Hospital Michael Ricci Joseph B. Nadol, Jr., M.D. Walter Augustus LeCompte Professor of Otology and Chief Information Officer Laryngology, Department of Otology and Laryngology, Harvard Medical School Peter Spivack Chief and Chair, Department of Otolaryngology, Chief Information Officer Massachusetts Eye and Ear Infirmary Hugh Curtin, M.D. Professor of Radiology, Harvard Medical School Chief of Radiology, Massachusetts Eye and Ear Infirmary Teresa C. Chen, M.D. Associate Professor, Department Associate Professor, Department of Ophthalmology, Harvard Medical School Chief Quality Officer, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary Christopher J. Hartnick, M.D. Professor, Department of Otology and Laryngology, Harvard Medical School Chief Quality Officer, Co-Director, Pediatric Airway/ Swallowing/Voice Center, Department of Otolaryngology, Massachusetts Eye and Ear Infirmary Eileen Lowell, R.N., M.M. Chief Nursing Officer, Massachusetts Eye and Ear Infirmary A Letter from the President Dear Colleagues in Healthcare, John Fernandez President & CEO, Massachusetts Eye and Ear is proud to present the 2012 Massachusetts Eye and Ear edition of Quality and Outcomes. Great outcomes are a direct result of highest-quality care and a commitment to continue to improve.
    [Show full text]
  • Department of Ophthalmology Quality and Outcomes
    Quality and Outcomes Department of Ophthalmology | 2019 Photo by Gulnara Niaz and Pierce Harman. Photo by Garyfallia Pagonis. Letter from the President 1 About the Quality and Outcomes Program 2 Ophthalmology Clinical Leadership 4 in Quality 2019 About Massachusetts Eye and Ear 5 Department of Ophthalmology Overview 6 Key Statistics 9 Emergency Department 10 Eye Trauma Surgery 13 Cataract Surgery 18 Retina Surgery 20 Table of Contents Table 25 Glaucoma Surgery 29 Refractive Surgery 34 Cornea Surgery 38 Oculoplastic Surgery 41 Adult Strabismus Service 44 Neuro-Ophthalmology Service 45 Pediatric and Adult Strabismus Surgery 50 Ocular Immunology and Uveitis Service 51 Vision Rehabilitation Service 52 Ophthalmology Medical Staff and Practice Locations 55 Contributors 56 Appendix 1 Leading the way in making outcomes data publicly available... Dear Colleagues in Health Care, hank you for reading the 2019 edition of the Mass. Eye and Ear Quality and Outcomes Report for the Department of Ophthalmology. This year’s book represents a special Tmilestone: 10 years of consistent reporting on specific outcomes measures throughout the field of ophthalmology. I am very proud that Mass. Eye and Ear has led the nation in Photo by Garyfallia Pagonis. defining appropriate ophthalmology measures, collecting data, and publishing that data with complete transparency. I continue to hope that more organizations and providers will join us in this effort to engage in public reporting. As you will read in the pages that follow, Mass. Eye and Ear has enhanced its quality efforts with a renewed focus on the patient’s overall experi- ence, an effort we expect to sustain for decades to come.
    [Show full text]
  • VEGF: from Discovery to Therapy: the Champalimaud Award Lecture
    DOI: 10.1167/tvst.5.2.9 Perspective VEGF: From Discovery to Therapy: The Champalimaud Award Lecture Joan W. Miller1 1 Department of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear, Massachusetts General Hospital, Boston, MA, USA Correspondence: Joan W. Miller, Purpose: Intraocular vascular diseases are leading causes of adult vision loss, and in Department of Ophthalmology, the mid-1900s, I. C. Michaelson postulated that the retina releases a soluble, diffusible Harvard Medical School, Massachu- factor that causes abnormal vascular growth and leakage. What became known as setts Eye and Ear, Massachusetts ‘‘Factor X’’ eluded investigators for decades. General Hospital, 243 Charles Street, Boston, MA 02114, USA. e-mail: Methods: The field of cancer research, where Judah Folkman pioneered the concept [email protected] of angiogenesis, provided the inspiration for the work honored by the 2014 Champalimaud Vision Award. Recognizing that tumors recruit their own blood supply Received: 12 October 2015 to achieve critical mass, Dr Folkman proposed that angiogenic factors could be Accepted: 15 October 2015 therapeutic targets in cancer. Napoleone Ferrara identified vascular endothelial Published: 11 March 2016 growth factor (VEGF) as such an angiogenic agent: stimulated by hypoxic tumor Keywords: age-related macular tissue, secreted, and able to induce neovascularization. VEGF also was a candidate for degeneration (AMD); angiogenesis; Factor X, and the 2014 Champalimaud Laureates and colleagues worked individually Antonio´ Champalimaud Vision and collaboratively to identify the role of VEGF in ocular disease. Award; Factor X; vascular endo- Results: The Champalimaud Laureates correlated VEGF with ocular neovascularization thelial growth factor (VEGF) in animal models and in patients.
    [Show full text]